Repligen Corporation is a leading global provider of bioprocessing technologies and solutions that support the development and manufacture of biologic drugs. Specializing in high-value consumable prod... Repligen Corporation is a leading global provider of bioprocessing technologies and solutions that support the development and manufacture of biologic drugs. Specializing in high-value consumable products, Repligen plays a pivotal role in the biotechnology and pharmaceutical sectors by supplying sophisticated products such as Protein A affinity ligands, advanced filtration systems, and ready-to-use chromatography columns—essential tools for the purification and production of complex biologics, including monoclonal antibodies. The company’s innovative portfolio serves major life sciences firms and contract manufacturing organizations worldwide, helping to increase efficiency, reliability, and yield in drug production processes. Headquartered in Waltham, Massachusetts, Repligen Corporation maintains a strong manufacturing footprint in Europe, underscoring its global reach and commitment to supporting the rapidly expanding biopharmaceutical market. With over 1,700 employees and continuous investment in research and development, Repligen is recognized for driving advancements in bioprocessing that are critical to meeting the growing demand for biologic therapies. Its contributions are integral to the lifecycle of next-generation medicines, making it a key enabler for both established and emerging biopharma companies.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for Repligen

We have not yet reviewed Repligen's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Repligen's data?

Create a free Tracenable account to signal interest in having our team review data for Repligen.

Legal Center Contact Us